Granules India has received the US Food & Drug Administration (FDA) approval for its Abbreviated New Drug Application (ANDA) for loperamide hydrochloride and simethicone tablets, 2 mg/125 mg (OTC). It is bioequivalent to the reference listed drug product, imodium multi-symptom relief tablets, 2 mg/125 mg, of Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Loperamide hydrochloride and simethicone tablets are indicated to relieve symptoms of diarrhoea plus bloating, pressure and cramps, commonly referred to as gas. Granules now have a total of 52 ANDA approvals from US FDA (50 Final approvals and 2 tentative approvals). The imodium multi-symptom relief brand and store brands had combined US sales of approximately $60 million MAT for the most recent twelve months.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!